Competitive Intelligence
Week ending September 6, 2026
1. Competitive landscape snapshot
AI answers about Ozempic named four competitors this week, totaling 40 raw mentions:
- Wegovy: 25 (62.5%)
- Trulicity: 7 (17.5%)
- Mounjaro: 7 (17.5%)
- Rybelsus: 1 (2.5%)
The strongest explicit comparison was Ozempic vs. Wegovy, generating 7 responses. Wegovy was also introduced in answers to the weight-management question (7 responses) and appeared incidentally in the Trulicity/Mounjaro labeling comparison, safety-warning, dosing, pregnancy, and substitution answers. Thus, approximately 7 of 25 Wegovy mentions came from a directly named comparison question; the remaining 18 were answer-introduced or incidental.
Trulicity and Mounjaro each appeared in all 7 responses to the explicit question comparing Ozempic with those products. Rybelsus appeared once, incidentally, in an interaction answer.
2. How the comparison is currently framed
Wegovy is the clearest competitive reference point, with framing that is mostly balanced but favors Wegovy in weight management. Answers consistently say Ozempic and Wegovy share semaglutide but are “not the same medicine” because their approved uses, formulations, and dosing differ. In the weight-loss question, answers repeatedly position Wegovy as the approved weight-management product, while describing Ozempic use without diabetes as potentially off-label. That gives Wegovy a distinct indication advantage rather than portraying it as clinically superior overall.
The head-to-head Ozempic/Wegovy answers are otherwise neutral: both are described as once-weekly semaglutide products, with the distinction centered on purpose and dose.
The Trulicity/Mounjaro comparison is also primarily label-based and noncommittal. Responses stress that Ozempic’s outcomes should be evaluated against each product’s own approved labeling and caution against assuming equivalent or superior benefits. Six of seven responses in that question carried overclaim_language tags, including “superior” or “leading,” but the excerpts generally present those terms as claims to avoid—not as AI-endorsed competitor claims. One Wegovy substitution answer also carried a “best” tag, but its substantive framing remained “no meaningful difference” when ingredient, dose, and delivery form match.
3. Movers — who’s gaining or losing ground
No competitor gained raw mentions this week. All tracked competitors declined alongside the sharp reduction in total responses from 120 to 81:
- Wegovy: 44 → 25 (-19)
- Mounjaro: 23 → 7 (-16)
- Trulicity: 22 → 7 (-15)
- Rybelsus: 12 → 1 (-11)
Across the full trend, Wegovy remains the persistent leader, peaking at 47 mentions on July 26 and staying ahead every week. Mounjaro and Trulicity have also consistently occupied the next tier. No new entrant appeared this week; Zepbound, Victoza, Saxenda, Bydureon, and Byetta fell to zero after appearing in prior weeks.
4. Questions worth watching
- “What’s the difference between Ozempic and Wegovy—are they the same medicine or just different brands?” (7 responses)
- “Can Ozempic be used for weight loss in people without diabetes, and what’s the approved indication?” (7 responses)
- “Compared with Trulicity or Mounjaro, what outcomes or benefits are actually supported by Ozempic’s FDA-approved labeling?” (7 responses)
- “If my prescription says Ozempic but my pharmacy offers a different brand of semaglutide, is there any meaningful difference?” (4 responses)
5. Recommended actions
- Continue priority monitoring of Wegovy, which represents 25 of 40 mentions and remains the dominant comparison over nine weeks.
- Track weight-management framing separately from overall brand comparison. Current AI answers give Wegovy a clear approved-indication association without claiming overall superiority.
- Review the Trulicity/Mounjaro comparison cluster next week for movement from label-based neutrality toward explicit efficacy or superiority positioning.
- Treat the semaglutide substitution question as an emerging category signal, particularly if mentions of compounded or alternative semaglutide products increase again.
- No material competitive-share shift is evident this week; the lower counts appear primarily volume-driven, so avoid interpreting declines as reduced competitive relevance.